Literature DB >> 20124164

Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize.

Evanthia Galanis, Jan C Buckner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20124164     DOI: 10.1200/JCO.2009.26.1149

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer.

Authors:  Robert Dreicer; Jorge Garcia; Brian Rini; Nicholas Vogelzang; Sandy Srinivas; Bradley Somer; Peipei Shi; Marek Kania; Derek Raghavan
Journal:  Invest New Drugs       Date:  2013-02-24       Impact factor: 3.850

2.  A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).

Authors:  Roy Rampling; Marc Sanson; Thiery Gorlia; Denis Lacombe; Christina Lai; Myriam Gharib; Walter Taal; Clemens Stoffregen; Rodney Decker; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2012-01-29       Impact factor: 12.300

Review 3.  The Novel PKCθ from Benchtop to Clinic.

Authors:  Rouba Hage-Sleiman; Asmaa B Hamze; Lina Reslan; Hadile Kobeissy; Ghassan Dbaibo
Journal:  J Immunol Res       Date:  2015-05-19       Impact factor: 4.818

4.  Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.

Authors:  Romain Pacaud; Mathilde Cheray; Arulraj Nadaradjane; François M Vallette; Pierre-François Cartron
Journal:  Theranostics       Date:  2015-01-01       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.